Substituted pyridines and methods of use

Abstract

The present disclosure provides inhibitors of activin receptor-like kinase 5 (ALK5). Also disclosed are methods to modulate the activity of ALK5 and methods of treatment of disorders mediated by ALK5.

1 . A compound of Formula (I): 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof, wherein:
 W is selected from CH and N; 
 X and Y are each independently selected from C and N; 
 a is an integer from 0 to 3; 
 R 1  is independently selected at each occurrence from R 10 ; 
 L 1  is selected from absent; C 1-6  alkylene, C 2-6  alkenylene, C 2-6  alkynylene, C 3-12  carbocycle, and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more R 10 ; 
 L 2  is selected from absent, —O—, —S—, —N(R 11 )—, —C(O)—, —C(O)O—, —OC(O)—, —OC(O)O—, —C(O)N(R 11 )—, —C(O)N(R 11 )C(O)—, —C(O)N(R 11 )C(O)N(R 11 )—, —N(R 11 )C(O)—, —N(R 11 )C(O)N(R 11 )—, —N(R 11 )C(O)O—, —OC(O)N(R 11 )—, —C(NR 11 )—, —N(R 11 )C(NR 11 )—, —C(NR 11 )N(R 11 )—, —N(R 11 )C(NR 11 )N(R 11 )—, —S(O) 2 —, —OS(O)—, —S(O)O—, —S(O)—, —OS(O) 2 , —S(O) 2 O—, —N(R 11 )S(O) 2 —, —S(O) 2 N(R 11 )—, —N(R 11 )S(O)—, —S(O)N(R 11 )—, —N(R 11 )S(O) 2 N(R 11 )—, and —N(R 11 )S(O)N(R 11 )—; 
 
         R 2  is independently selected at each occurrence from R 10 ; 
         R 3 , R 4 , and R 5  are each independently absent or selected from R 11 ; 
         R 10  is independently selected at each occurrence from:
 halogen, —NO 2 , —CN, —OR 12 , —SR 12 , —N(R 12 ) 2 , —NR 13 R 14 , —S(═O)R 12 , —S(═O) 2 R 12 , —S(═O) 2 N(R 12 ) 2 , —S(═O) 2 NR 13 R 14 , —NR 12 S(═O) 2 R 12 , —NR 12 S(═O) 2 N(R 12 ) 2 , —NR 12 S(═O) 2 NR 13 R 14 , —C(O)R 12 , —C(O)OR 12 , —OC(O)R 12 , —OC(O)OR 12 , —OC(O)N(R 12 ) 2 , —OC(O)NR 13 R 14 , —NR 12 C(O)R 12 , —NR 12 C(O)OR 12 , —NR 12 C(O)N(R 12 ) 2 , —NR 12 C(O)NR 13 R 14 , —C(O)N(R 12 ) 2 , —C(O)NR 13 R 14 , —P(O)(OR 12 ) 2 , —P(O)(R 12 ) 2 , ═O, ═S, ═N(R 12 ); 
 C 1-10  alkyl, C 2-10  alkenyl, and C 2-10  alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, —NO 2 , —CN, —OR 12 , —SR 12 , —N(R 12 ) 2 , —NR 13 R 14 , —S(═O)R 12 , —S(═O) 2 R 12 , —S(═O) 2 N(R 12 ) 2 , —S(═O) 2 NR 13 R 14 , —NR 12 S(═O) 2 R 12 , —NR 12 S(═O) 2 N(R 12 ) 2 , —NR 12 S(═O) 2 NR 13 R 14 , —C(O)R 12 , —C(O)OR 12 , —OC(O)R 12 , —OC(O)OR 12 , —OC(O)N(R 12 ) 2 , —OC(O)NR 13 R 14 , —NR 12 C(O)R 12 , —NR 12 C(O)OR 12 , —NR 12 C(O)N(R 12 ) 2 , —NR 12 C(O)NR 13 R 14 , —C(O)N(R 12 ) 2 , —C(O)NR 13 R 14 , —P(O)(OR 12 ) 2 , —P(O)(R 12 ) 2 , ═O, ═S, ═N(R 12 ), C 3-12  carbocycle, and 3- to 12-membered heterocycle; and 
 C 3-12  carbocycle and 3- to 12-membered heterocycle, 
 wherein each C 3-12  carbocycle and 3- to 12-membered heterocycle in R 10  is independently optionally substituted with one or more substituents selected from halogen, —NO 2 , —CN, —OR 12 , —SR 12 , —N(R 12 ) 2 , —NR 13 R 14 , —S(═O)R 12 , —S(═O) 2 R 12 , —S(═O) 2 N(R 12 ) 2 , —S(═O) 2 NR 13 R 14 , —NR 12 S(═O) 2 R 12 , —NR 12 S(═O) 2 N(R 12 ) 2 , —NR 12 S(═O) 2 NR 13 R 14 , —C(O)R 12 , —C(O)OR 12 , —OC(O)R 12 , —OC(O)OR 12 , —OC(O)N(R 12 ) 2 , —OC(O)NR 13 R 14 , —NR 12 C(O)R 12 , —NR 12 C(O)OR 12 , —NR 12 C(O)N(R 12 ) 2 , —NR 12 C(O)NR 13 R 14 , —C(O)N(R 12 ) 2 , —C(O)NR 13 R 14 , —P(O)(OR 12 ) 2 , —P(O)(R 12 ) 2 , ═O, ═S, ═N(R 12 ), R 12 , C 1-6  alkyl, C 1-6  haloalkyl, C 2-6  alkenyl, and C 2-6  alkynyl; 
 
         R 11  is independently selected at each occurrence from:
 hydrogen, —C(O)R 12 , —C(O)OR 12 , —C(O)N(R 12 ) 2 , —C(O)NR 13 R 14 ; 
 C 1-6  alkyl, C 2-6  alkenyl, and C 2-6  alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, —NO 2 , —CN, —OR 12 , —SR 12 , —N(R 12 ) 2 , —NR 13 R 14 , —S(═O)R 12 , —S(═O) 2 R 12 , —S(═O) 2 N(R 12 ) 2 , —S(═O) 2 NR 13 R 14 , —NR 12 S(═O) 2 R 12 , —NR 12 S(═O) 2 N(R 12 ) 2 , —NR 12 S(═O) 2 NR 13 R 14 , —C(O)R 12 , —C(O)OR 12 , —OC(O)R 12 , —OC(O)OR 12 , —OC(O)N(R 12 ) 2 , —OC(O)NR 13 R 14 , —NR 12 C(O)R 12 , —NR 12 C(O)OR 12 , —NR 12 C(O)N(R 12 ) 2 , —NR 12 C(O)NR 13 R 14 , —C(O)N(R 12 ) 2 , —C(O)NR 13 R 14 , —P(O)(OR 12 ) 2 , —P(O)(R 12 ) 2 , ═O, ═S, ═N(R 12 ), C 3-12  carbocycle, and 3- to 12-membered heterocycle; and 
 C 3-12  carbocycle and 3- to 12-membered heterocycle, 
 wherein each C 3-12  carbocycle and 3- to 12-membered heterocycle in R 11  is independently optionally substituted with one or more substituents selected from halogen, —NO 2 , —CN, —OR 12 , —SR 12 , —N(R 12 ) 2 , —NR 13 R 14 , —S(═O)R 12 , —S(═O) 2 R 11 , —S(═O) 2 N(R 12 ) 2 , —S(═O) 2 NR 13 R 14 , —NR 12 S(═O) 2 R 12 , —NR 12 S(═O) 2 N(R 12 ) 2 , —NR 12 S(═O) 2 NR 13 R 14 , —C(O)R 12 , —C(O)OR 12 , —OC(O)R 12 , —OC(O)OR 12 , —OC(O)N(R 12 ) 2 , —OC(O)NR 13 R 14 , —NR 12 C(O)R 12 , —NR 12 C(O)OR 12 , —NR 12 C(O)N(R 12 ) 2 , —NR 12 C(O)NR 13 R 14 , —C(O)N(R 12 ) 2 , —C(O)NR 13 R 14 , —P(O)(OR 12 ) 2 , —P(O)(R 12 ) 2 , ═O, ═S, ═N(R 12 ), R 12 , C 1-6  alkyl, C 1-6  haloalkyl, C 2-6  alkenyl, and C 2-6  alkynyl; 
 
         R 12  is independently selected at each occurrence from hydrogen; and C 1-10  alkyl, C 2-10  alkenyl, C 2-10  alkynyl, 1- to 6-membered heteroalkyl, C 3-12  carbocycle, and 3- to 12-membered heterocycle, each of which is optionally substituted by halogen, —CN, —NO 2 , —NH 2 , —NHCH 3 , —NHCH 2 CH 3 , ═O, —OH, —OCH 3 , —OCH 2 CH 3 , —CH 3 , —CH 2 CH 3 , —CH(CH 3 ) 2 , —C(CH 3 ) 3 , C 3-12  carbocycle, or 3- to 6-membered heterocycle; and 
         R 13  and R 14  are taken together with the nitrogen atom to which they are attached to form a heterocycle, optionally substituted with one or more R 12 . 
       
     
     
         2 . The compound or salt of  claim 1 , wherein W is N. 
     
     
         3 . The compound or salt of  claim 1 , wherein W is CH. 
     
     
         4 .- 9 . (canceled) 
     
     
         10 . The compound or salt of  claim 1 , wherein a is 1 or 2. 
     
     
         11 . (canceled) 
     
     
         12 . The compound or salt of  claim 1 , wherein the compound is a compound of Formula (I-B): 
       
         
           
           
               
               
           
         
       
     
     
         13 . The compound or salt of  claim 1 , wherein the compound is a compound of Formula (I-C): 
       
         
           
           
               
               
           
         
       
     
     
         14 . The compound or salt of  claim 1 , wherein R 1  is selected from halogen, C 1-4  alkyl and C 1-4  haloalkyl. 
     
     
         15 . (canceled) 
     
     
         16 . The compound or salt of  claim 1 , wherein L 1  is selected from absent, C 1-6  alkylene, C 3-12  carbocycle and 3- to 12-membered heterocycle. 
     
     
         17 .- 19 . (canceled) 
     
     
         20 . The compound or salt of  claim 1 , wherein L 2  is selected from absent, —O—, —N(R 11 )—, —C(O)O—, —C(O)N(R 11 )— and —N(R 11 )C(O)—. 
     
     
         21 .- 23 . (canceled) 
     
     
         24 . The compound or salt of  claim 1 , wherein R 2  is selected from:
 halogen, —CN, —OR 12 , —SR 12 , —N(R 12 ) 2 , —C(O)OR 12 , —OC(O)R 12 , —NR 12 C(O)R 12 , —NR 12 C(O)N(R 12 ) 2 , —C(O)N(R 12 ) 2 ;   C 1-10  alkyl, optionally substituted with one or more substituents selected from halogen, —CN, —OR 12 , —SR 12 , —N(R 12 ) 2 , —C(O)OR 12 , —OC(O)R 12 , —NR 12 C(O)R 12 , —NR 12 C(O)N(R 12 ) 2 , —C(O)N(R 12 ) 2 , C 3-12  carbocycle, and 3- to 12-membered heterocycle; and   C 3-12  carbocycle and 3- to 12-membered heterocycle,   wherein each C 3-12  carbocycle and 3- to 12-membered heterocycle in R 12  is independently optionally substituted with one or more substituents selected from halogen, —CN, —OR 12 , —SR 12 , —N(R 12 ) 2 , —C(O)OR 12 , —OC(O)R 12 , —NR 12 C(O)R 12 , —NR 12 C(O)N(R 12 ) 2 , —C(O)N(R 12 ) 2 , ═O, R 12 , C 1-6  alkyl, and C 1-6  haloalkyl.   
     
     
         25 .- 32 . (canceled) 
     
     
         33 . The compound or salt of  claim 1 , wherein the stereoisomer is provided in at least 90% enantiomeric excess. 
     
     
         34 . (canceled) 
     
     
         35 . A pharmaceutical composition comprising the compound or salt of  claim 1  and a pharmaceutically acceptable carrier. 
     
     
         36 . The pharmaceutical composition of  claim 35 , wherein the pharmaceutical composition is formulated for inhalation. 
     
     
         37 . (canceled) 
     
     
         38 . A method of treating an ALK5-mediated disease or condition in a subject, comprising administering to the subject a therapeutically effective amount of the compound or salt of  claim 1 . 
     
     
         39 . (canceled) 
     
     
         40 . The method of  claim 38 , wherein the disease or condition is fibrosis. 
     
     
         41 .- 42 . (canceled) 
     
     
         43 . The method of  claim 40 , where the fibrosis is selected from cardiac fibrosis, kidney fibrosis, pulmonary fibrosis, liver fibrosis, portal vein fibrosis, skin fibrosis, bladder fibrosis, intestinal fibrosis, peritoneal fibrosis, myelofibrosis, oral submucous fibrosis, and retinal fibrosis. 
     
     
         44 . The method of  claim 43 , where the pulmonary fibrosis is selected from idiopathic pulmonary fibrosis (IPF), familial pulmonary fibrosis (FPF), interstitial lung fibrosis, fibrosis associated with asthma, fibrosis associated with chronic obstructive pulmonary disease (COPD), silica-induced fibrosis, asbestos-induced fibrosis and chemotherapy-induced lung fibrosis. 
     
     
         45 . The method of  claim 43 , where the pulmonary fibrosis is idiopathic pulmonary fibrosis (IPF). 
     
     
         46 . (canceled) 
     
     
         47 . The method of  claim 40 , where the fibrosis is intestinal fibrosis. 
     
     
         48 . (canceled) 
     
     
         49 . The method of  claim 48 , wherein the cancer is selected from breast cancer, colon cancer, prostate cancer, lung cancer, hepatocellular carcinoma, glioblastoma, melanoma, and pancreatic cancer. 
     
     
         50 . The method of  claim 49 , wherein the lung cancer is non-small cell lung cancer. 
     
     
         51 . The method of  claim 38 , comprising administering a second therapeutic agent. 
     
     
         52 . The method of  claim 51 , wherein the second therapeutic agent is an immunotherapeutic agent. 
     
     
         53 .- 55 . (canceled) 
     
     
         56 . The method of  claim 38 , wherein the compound or salt is administered by inhalation. 
     
     
         57 .- 58 . (canceled)